Clobetasone Propionate
(Synonyms: Clobetasone 17-Propionate) 目录号 : GC49680
A corticosteroid
Cas No.:25122-56-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Clobetasone propionate is a corticosteroid.1 Formulations containing clobetasol propionate have been used in the treatment of eczema, psoriasis, and lupus.
1.Brandi, N., Starace, M., Alessandrini, A., et al.Tinea versicolor of the neck as side effect of topical steroids for alopecia areataJ. Dermatolog. Treat.30(8)757-759(2019)
| Cas No. | 25122-56-9 | SDF | Download SDF |
| 别名 | Clobetasone 17-Propionate | ||
| Canonical SMILES | CCC(O[C@]1([C@@]2([C@@]([C@@]3([H])[C@](C(C2)=O)([C@@]4(C(CC3)=CC(C=C4)=O)C)F)([H])C[C@@H]1C)C)C(CCl)=O)=O | ||
| 分子式 | C25H30ClFO5 | 分子量 | 465 |
| 溶解度 | Acetone: slightly,Chloroform: slightly,DMSO: slightly | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1505 mL | 10.7527 mL | 21.5054 mL |
| 5 mM | 0.4301 mL | 2.1505 mL | 4.3011 mL |
| 10 mM | 0.2151 mL | 1.0753 mL | 2.1505 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Desquamative inflammatory vaginitis: what is it?
J Reprod Med 2008 Feb;53(2):124-8.PMID:18357804doi
Objective: To record the inflammatory patterns found in desquamative inflammatory vaginitis and to investigate further the existence of an idiopathic subset of this condition. Study design: This was a retrospective case note study of 11 women over a 12-month period who presented with symptoms of painful sexual intercourse and increased vaginal discharge. Results: Examination of the vulva was usually normal or showed mild erythema and a thin purulent discharge. Examination of the vaginal wall showed erythema consistent with inflammation. A biopsy from the vaginal wall showed essentially 2 patterns of inflammation: either a lichenoid or a nonspecific mixed inflammatory infiltrate. Therapy with clindamycin and Clobetasone Propionate was largely effective. Conclusion: While this study does not fully answer the histology of desquamative inflammatory vaginitis, it does highlight the need for further study to identify whether there is an idiopathic subset of desquamative inflammatory vaginitis or whether it is erosive lichen planus.
Tinea versicolor of the neck as side effect of topical steroids for alopecia areata
J Dermatolog Treat 2019 Dec;30(8):757-759.PMID:30668183DOI:10.1080/09546634.2019.1573308.
Background: Treatment of alopecia areata (AA) involves use of high potency topical corticosteroids under occlusion that, even very effective, can lead to several adverse effects. Objective: We report 10 cases of patients with AA that, after using high potency topical corticosteroids, have developed tinea versicolor of the neck area. Methods: Ten patients with AA, aged 18-38 years, were prescribed with Clobetasone Propionate 0.05% cream under occlusion every other day but, after 3-4 months of treatment, they returned to our facility complaining the appearance of multiple white or red-brown round or oval macules in the neck area. Results: Diagnosis of pityriasis versicolor was confirmed by direct microscopy examination of skin scrapings in 10% potassion hydroxide (KOH) solution. All patients received systemic antifungal therapy associated with the daily use of ketoconazole shampoo. Conclusion: Tinea versicolor of the neck should be included among a rare but possible side effect of prolonged application of high potency topical steroids on the scalp. These cases reinforce the importance of careful dermatologic examination and recommend preventive measures in patients with alopecia areata that are using these drugs.
Liquid chromatographic determination of clobetasone-17-butyrate in ointments
J Assoc Off Anal Chem 1990 Nov-Dec;73(6):893-5.PMID:2289922doi
A liquid chromatographic (LC) method has been developed for determination of clobetasone-17-butyrate in ointment using Clobetasone Propionate as an internal standard. Separation was carried out on a C18 reverse-phase column using water-methanol as a mobile phase. Methylparaben and propylparaben (both sodium salt) used as preservatives did not interfere with separation. Compounds are detected photometrically at 235 nm. Mean assay results for 0.05% commercial ointments were 100.36% (n = 5). Mean recovery of clobetasone-17-butyrate added to commercial ointment was 99.89%.
Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough
Indian J Pharmacol 2021 Sep-Oct;53(5):371-376.PMID:34854405DOI:10.4103/ijp.IJP_728_19.
Objectives and methods: In September 2018, the government of India banned 328 fixed dose combinations (FDCs), 24 of which are combinations containing topical steroids. To assess what impact can be expected from this regulatory action, we analyzed reports of adverse drug events due to topical corticosteroids at a hospital-based pharmacovigilance center between January 2017 and August 2018. Results: Among 34 different steroid-containing FDCs responsible for 485 reports of ADEs with topical steroids, only three preparations, accounting for 50.10% of ADEs, come under the umbrella of the recent ban. Clobetasone Propionate (68.87%) and betamethasone (28.45%) were the corticosteroids most frequently associated with adverse events. Most of the steroid preparations (87.84%) had been bought without a prescription for the treatment of dermatophytoses (76.70%). Males (77.73%) were predominantly affected, and nearly half (47.43%) of the patients were between 21 and 30 years of age. Skin atrophy (50.10%), striae (25.54%), and hypopigmentation (19.79%) were the major ADEs. Conclusion: Nearly half of the cutaneous adverse effects were due to topical steroid combinations which are still widely available over the counter.